This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Taking T2DM to Heart: Treating to Decrease CVD—Part 1

Taking T2DM to Heart: Treating to Decrease CVD—Part 1


Slide Lecture Series

Time to Complete

45 minutes


May 31, 2019


May 31, 2020

Maximum Credits

0.75 / AMA PRA Category 1 CreditTM

Accredited Provider

This activity is provided by Forefront Collaborative.

Commercial Supporter

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Program Description

Patients with type 2 diabetes mellitus (T2DM) face increased risk for coronary heart disease and other vascular disorders, including heart failure, cardiac dysrhythmia, sudden death, hypertensive disease, pulmonary embolism, and aortic aneurysm. In Part 1 of this education, Dr. Richard Pratley will present A New Look at Current Clinical Guidelines, CVOT, and Evidence-based Treatment Options and discuss current data and equip learners with strategies to address patient barriers and to apply emerging and adjunctive therapies to daily clinical practice. This activity will focus on key clinical guideline updates and their application for individualizing care plans and minimizing negative cardiovascular outcomes in T2DM. Learners will also be provided with a summary of safety/efficacy data of new and emerging therapies to reduce the risk of cardiovascular disease (CVD), renal comorbidities, and CVD death.

Intended Audience

The target audience for this activity includes members of the diabetes care team (eg, primary care physicians, nurse practitioners, physician assistants, internal medicine physicians, endocrinologists, cardiologists, and diabetes educators). Other healthcare professionals who treat or manage patients with diabetes may also benefit from participation.

Educational Objectives

Upon completion of the activity, participants should be able to:

  • Summarize evidence-based practice guidelines for glycemic control in patients with T2DM.
  • Describe the efficacy/safety profiles of available antihyperglycemic agents and their impact on cardiovascular and renal issues in patients with T2DM.
  • Outline clinical trial data of specific sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 receptor agonists (GLP-1 RAs), and dipeptidyl peptidase-4 inhibitors (DPP-4is) in patients with T2DM as demonstrated in cardiovascular outcomes trials (CVOTs).

Fee Information

There is no fee for this educational activity.

Conflict Of Interest Disclosure Policy

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.


Richard Pratley, MD
Samuel E. Crockett Chair in Diabetes Research,
Medical Director,
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead,
Translational Research Institute for Metabolism and Diabetes
Orlando, Florida

Dr. Pratley discloses the following:
Consultant: AstraZeneca, GlaxoSmithKline, Glytec, Janssen, Ligand, Lilly, Merck, Mundipharma, Novo, Pfizer, and Sanofi;
Speaker’s Bureau: Novo
Grant Funding: Janssen, Lexicon, Ligand, Lilly, Merck, Novo, and Sanofi

Accredited Provider Disclosure

Forefront Collaborative
Sydney Pate
has nothing to disclose in regards to financial relationship(s) with commercial interest.
Maria Rovere has nothing to disclose in regards to financial relationship(s) with commercial interest.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Forefront Collaborative designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This continuing medical education activity may include reference(s) to unlabeled or unapproved uses of drugs.


The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative or Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.


To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue

Related to this activity